Alerts will be sent to your verified email
Verify Email
GLAND
|
Gland Pharma
|
Caplin Point Lab
|
Gufic Biosciences
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Pharmaceuticals
|
|||
|
Number of ANDA's Filed in USA
|
378.0 . | 52.0 . | n/a |
|
Number of ANDA's Approved By USFDA
|
329.0 . | 42.0 . | n/a |
|
US DMF Filings
|
68.0 . | n/a | n/a |
|
Unclassified
|
|||
|
R&D as a % of Total Sales
|
5.8 % | 4.02 % | 1.28 % |
|
API Capacity
|
11000.0 Kg/Year | n/a | n/a |
|
Financials
|
|||
|
5 yr Average ROE
|
12.02 % | 19.84 % | 16.89 % |
|
5yr average Equity Multiplier
|
1.15 | 1.15 | 2.16 |
|
5yr Average Asset Turnover Ratio
|
0.51 | 0.68 | 0.75 |
|
5yr Avg Net Profit Margin
|
20.79 % | 25.35 % | 10.24 % |
|
Price to Book
|
3.13 | 4.61 | 5.44 |
|
P/E
|
37.87 | 24.76 | 60.3 |
|
5yr Avg Cash Conversion Cycle
|
69.81 Days | 70.68 Days | -15.25 Days |
|
Inventory Days
|
118.26 Days | 66.07 Days | 71.73 Days |
|
Days Receivable
|
99.92 Days | 110.7 Days | 106.89 Days |
|
Days Payable
|
107.43 Days | 85.23 Days | 179.29 Days |
|
5yr Average Interest Coverage Ratio
|
183.05 | 633.04 | 8.9 |
|
5yr Avg ROCE
|
16.55 % | 24.45 % | 17.89 % |
|
5yr Avg Operating Profit Margin
|
29.26 % | 31.52 % | 18.12 % |
|
5 yr average Debt to Equity
|
0.01 | 0.0 | 0.67 |
|
5yr CAGR Net Profit
|
-6.87 % | 17.23 % | -2.66 % |
|
5yr Average Return on Assets
|
10.65 % | 17.23 % | 7.7 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
51.83 % | 70.57 % | 72.5 % |
|
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
-6.03 % | 1.69 % | -2.5 % |
|
Change in Mutual Fund Holding (3 Yrs)
|
11.71 % | 0.74 % | 2.45 % |
|
Gland Pharma
|
Caplin Point Lab
|
Gufic Biosciences
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
|
Distribution Channel
|
Distribution Channel
|
Distribution Channel
|
-
|